<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="26995">Thromboxane</z:chebi> A(2) (TxA(2)) is assumed to contribute to the development of <z:mp ids='MP_0002055'>diabetes</z:mp> complications, including <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated whether the selective <z:chebi fb="0" ids="26995">thromboxane</z:chebi>-<z:chebi fb="0" ids="26347">prostanoid</z:chebi> endoperoxide receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, S18886, ameliorates renal damage in uninephrectomized (UNX) <z:mp ids='MP_0001261'>obese</z:mp> <z:chebi fb="3" ids="16646">Zucker</z:chebi> rats (OZR) </plain></SENT>
<SENT sid="2" pm="."><plain>S18886, at doses of 10 (S18886-10) and 30 (S18886-30) mg x kg(-1) x day(-1), was administered to UNX-OZR by gavage over 8 weeks (n = 8 each group) </plain></SENT>
<SENT sid="3" pm="."><plain>UNX lean rats (n = 12) and OZR rats that received placebo (OZR-PLAC, n = 8) served as controls </plain></SENT>
<SENT sid="4" pm="."><plain>As compared with the OZR-PLAC, S18886 had no significant effect on the elevated blood pressure and the enhanced <z:chebi fb="0" ids="16737">creatinine</z:chebi> clearance, while augmented <z:hpo ids='HP_0000093'>proteinuria</z:hpo> was partially prevented (-12 and -37%, low and high dose, respectively; NS) </plain></SENT>
<SENT sid="5" pm="."><plain>The increased excretion of transforming growth factor beta(1) (TGF-beta(1)) and of the <z:chebi fb="0" ids="26995">thromboxane</z:chebi> metabolite 2,3-dinor <z:chebi fb="0" ids="26995">thromboxane</z:chebi> B(2) (TxB(2)) was lowered (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>S18886 prevented both the enhanced <z:mp ids='MP_0011430'>mesangiolysis</z:mp> (P &lt; 0.01) in the OZR-PLAC as well as enlargement and degeneration of podocytes </plain></SENT>
<SENT sid="7" pm="."><plain>In the blood, S18886-30 augmented the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> enzymes (P &lt; 0.01) and lessened the increase of plasma advanced oxidation protein products (-25%, NS) </plain></SENT>
<SENT sid="8" pm="."><plain>Body weight, <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> remained uninfluenced under both doses of treatment </plain></SENT>
<SENT sid="9" pm="."><plain>S18886 has renoprotective properties in the model of UNX-OZR </plain></SENT>
<SENT sid="10" pm="."><plain>It prevents <z:mp ids='MP_0011430'>mesangiolysis</z:mp>, reduces urinary TGF-beta(1) and 2,3-dinor-TxB(2) excretion, and enhances the antioxidative defense </plain></SENT>
</text></document>